Chimerix (NASDAQ:CMRX)‘s stock had its “hold” rating restated by investment analysts at Cowen in a research note issued on Thursday. They currently have a $6.00 price target on the biopharmaceutical company’s stock. Cowen’s target price would suggest a potential upside of 66.67% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Thursday, October 4th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Chimerix in a report on Friday, September 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Chimerix currently has an average rating of “Hold” and a consensus target price of $6.75.

Shares of NASDAQ:CMRX opened at $3.60 on Thursday. The firm has a market cap of $176.26 million, a price-to-earnings ratio of -2.38 and a beta of 0.91. Chimerix has a one year low of $3.53 and a one year high of $5.94.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. The firm had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $0.94 million. Chimerix had a negative return on equity of 34.94% and a negative net margin of 1,582.64%. Equities research analysts forecast that Chimerix will post -1.66 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC acquired a new stake in shares of Chimerix during the first quarter worth $127,000. Wells Fargo & Company MN boosted its holdings in shares of Chimerix by 46.1% during the first quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 10,598 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of Chimerix during the first quarter worth $252,000. Acadian Asset Management LLC boosted its holdings in shares of Chimerix by 63.3% during the second quarter. Acadian Asset Management LLC now owns 155,067 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 60,087 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new stake in shares of Chimerix during the second quarter worth $917,000. Institutional investors and hedge funds own 72.98% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Further Reading: Trading Strategy Methods and Types

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.